Helius Medical Technologies, Inc. Stock News

Dr. Favit-Van Pelt will present research that led to the FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis Dr. Favit-Van Pelt will present research that led to the FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis

Dr. Favit-Van Pelt will present research that led to the FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis Dr. Favit-Van Pelt will present research that le

Helius Medical Technologies (NASDAQ:HSDT) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Monday, Zacks.com reports. According to Zacks, Helius Medical Technologies Inc. is a specialty medical device company. It is focused on the development and regulatory approval of its non-invasive neurostimulation device called []

Trimedyne (OTCMKTS:TMED) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Analyst Recommendations This is a breakdown of current recommendations and price targets for []

Zacks Investment Research lowered shares of Helius Medical Technologies (NASDAQ:HSDT) from a buy rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports. According to Zacks, Helius Medical Technologies Inc. is a specialty medical device company. It is focused on the development and regulatory approval of its non-invasive neurostimulation device []

Helius Medical Technologies, Inc. (NASDAQ:HSDT) CEO Dane Andreeff bought 37,500 shares of the companys stock in a transaction on Friday, November 12th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $300,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which []

Related Stocks: HSDT ,

Dane Andreeff , CEO at Helius Medical Tech (NASDAQ: HSDT ), made a large insider buy on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Andreeff purchased 37,500 shares of Helius Medical Tech at at a price of $8.00. The total transaction amounted to $300,000. Andreeff now owns a total of 6,142 of Helius Medical Tech worth, 50,732. Helius Medical Tech shares are trading up 1.85% at $8.26 at the time of this writing on Monday morning. Now trade stocks online commission free with Charles Schwab, a Full story available on Benzinga.com

NEWTOWN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (Helius), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff

NEWTOWN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (Helius), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer, will participate in 1x1 meetings at the 12th Annual Craig-Hallum Alpha Select Conference, being held virtually on Tuesday, November 16, 2021.

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -14.86% and 37.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahea

NEWTOWN, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ

NEWTOWN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) --  Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today anno

NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ

NEWTOWN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, to